Moderna Therapeutics, a Cambridge, Mass.-based developer of pioneering messenger RNA Therapeutics™, an entirely new treatment modality that enables the body to produce therapeutic proteins in vivo, has closed more than $40m in financing.
The investment was led by Flagship Ventures and private investors.
The company intends to use the company to advance multiple programs toward clinical stage development.
Founded within Flagship VentureLabs by Stephane Bancel, president and CEO, Moderna is pioneering messenger RNA Therapeutics™, a novel biotherapeutic modality with the capability of stimulating the body’s natural ability to produce therapeutic proteins. Over the past 18 months, the company has conducted proof-of-concept studies in preclinical models, including non-human primates, and has demonstrated the ability to induce in vivo production of dozens of intracellular and secreted therapeutic proteins through intramuscular, subcutaneous or intravenous administration across multiple preclinical models. The company will present the results of these studies in 2013.
The management team of the company also include:
– Susan Whoriskey, Ph.D., senior vice president of technology strategy,
– Tony de Fougerolles, Ph.D., Chief scientific officer,
– Louis O’Dea, MB, BCh, BAO, chief medical officer and head of regulatory affairs,
– Noubar Afeyan, co-founder and chairman.